甲磺酸伊马替尼治疗慢性粒细胞白血病的临床观察

目的评价甲磺酸伊马替尼治疗慢性粒细胞白血病（CML）临床疗效，及其安全性。方法应用甲磺酸伊马替尼治疗慢性粒细胞白血病患者共40例，检测血液学、细胞遗传学疗效。结果CML血液学完全缓解率为65．0％，其中CML—AP、CML—BC、CML-CP血液完全缓解率分别为57．14％，50．0％，7619％，Ph染色体转阴率为42．3％；所有患者接受治疗后均出现不同程度的白细胞，血红蛋白及血小板减少，经过对症治疗处理均顺利完成观察。结论伊马替尼治疗慢性粒细胞白血病有较高的完全血液学缓解率和遗传学缓解率不良反应轻微。

Clinical observation of imatinib in treatment of patients With chronic myeloid leukemia

Objective To evaluate the efficacy and safety of imatinib in treatment of patients with chronic myeloid leukemia （CML）.Methods Using imatinib in treatment of 40 patients with chronic myeloid leukemia patients, detected of hematology, cytogenetic and evaluated effects. Results There were 65.0% of patients achieving complete hematologic response, completing hematologic response rate of CML-AP, CML-BC , CML-CP were 57.14%, 50.0%, 76.19%. The rate of Ph chromosome negative conversion was 42.3%.After treatment there are different levels reduction of white blood cells, hemoglobin and thromboeytopenia in the patients. They successfully completed the clinical observation after appropriate treatment. Conclusion Imatinib induced high rate of cytogenetic and hematologic responses in patients with chronic myeloid leukemia, and the adverse effects were mild.